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Abstract 
 
Despite that advanced maternal age at conception represents the major risk factor for the birth of a 
child with Down syndrome (DS), most of DS babies are born from women aging less than 35 years. 
Studies performed in peripheral lymphocytes of those women revealed several markers of global 
genome instability, including an increased frequency of micronuclei, shorter telomeres and 
impaired global DNA methylation. Furthermore, young mothers of DS individuals (MDS) are at 
increased risk to develop dementia later in life, suggesting that they might be “biologically older” 
than mothers of euploid babies of similar age. 
      Mutations in folate pathway genes, and particularly in the methylenetetrahydrofolate reductase 
(MTHFR) one, have been often associated with maternal risk for a DS birth as well as with risk of 
dementia in the elderly. Recent studies pointed out that also changes in MTHFR methylation levels 
can contribute to human disease, but nothing is known about MTHFR methylation in MDS tissues. 
      We investigated MTHFR promoter methylation in DNA extracted from perypheral lymphocytes 
of 40 MDS and 44 matched control women that coinceived their children before 35 years of age, 
observing a significantly increased MTHFR promoter methylation in the first group (33.3 ± 8.1% 
vs. 28.3 ± 5.8%; p = 0.001). In addition, the frequency of micronucleated lymphocytes was 
available from the women included in the study, was higher in MDS than control mothers (16.1 ± 
8.6‰ vs. 10.5 ± 4.3‰; p = 0.0004), and correlated with MTHFR promoter methylation levels (r = 
0.33; p = 0.006). 
      Present data suggest that MTHFR epimutations are likely to contribute to the increased genomic 
instability observed in cells from MDS, and could play a role in the risk of birth of a child with DS 
as well as in the onset of age related diseases in those women. 
 
 
Keywords: methylenetetrahydrofolate reductase; MTHFR; Down syndrome; mothers; epigenetics; 
folate; methylation; micronuclei. 
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1. Introduction 
 
      Primary trisomy 21 leading to Down syndrome (DS) originates, in the majority of the cases, 
from the failure of normal chromosome segregation during maternal meiosis (meiotic 
nondisjunction), and the major risk factor is advanced maternal age at conception [1]. Indeed, after 
maternal age 35 years, the risk for a DS pregnancy increases for several years proportionally to 
increasing maternal age [1]. However, most of DS babies are born from women aging less than 35 
years at conception, and this has led to an intense investigation of factors that could contribute to 
DS risk in young women [2]. 
      The micronucleus assay revealed that young mothers of DS individuals (MDS) have an 
increased susceptibility to chromosome damage and malsegregation events in peripheral 
lymphocytes than control mothers [3-6]. Additionally, the analysis of telomere lenght in peripheral 
lymphocytes showed that women who conceived a DS child before 35 years of age have shorter 
telomeres than matched control mothers, suggesting that they might be "biologically older" than 
mothers of euploid babies in the same age group [7]. Interestingly, young MDS were also found to 
have a five-fold increased risk to develop Alzheimer’s disease later in life [8,9]. More recently, 
altered global DNA methylation levels, evaluated as Long Interspersed Nucleotide Element-1 
(LINE1) methylation, were observed in the DNA extracted from peripheral blood lymphocytes of 
young MDS compared to control mothers, suggesting that DNA methylation reactions are impaired 
in those women and that this might contribute to chromosome 21 malsegregation events [10]. 
Collectively, those studies revealed that peripheral lymphocytes of women who conceived a child 
with DS in young age show several markers of global genome instability.  
      In 1999 a case-control study conducted in North America suggested that genes encoding 
enzymes involved in folate metabolism could act as maternal risk factors for the birth of a child 
with DS [11]. In particular, the authors observed an increased frequency of the 
methylenetetrahydrofolate reductase (MTHFR) 677C>T polymorphism (rs1801133) in MDS than in 
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control mothers [11]. MTHFR catalyzes the reduction of 5,10-methylenetetrahydrofolate to 5-
methyltetrahydrofolate, which is required for the remethylation of homocysteine (Hcy) to 
methionine in the trans-methylation pathway. Methionine can then be converted to S-
adenosylmethionine (SAM), the intracellular donor of methyl groups for methylation reactions [12]. 
The MTHFR 677T allele results in decreased protein activity leading to increased Hcy levels and 
impaired DNA methylation [12]. Therefore, James and coworkers [11] hypothesized that 
impairments of folate metabolism, resulting from the presence of polymorphisms in metabolic 
genes, could lead to aberrant methylation of peri-centromeric regions of chromosome 21, favouring 
its abnormal segregation during maternal meiosis and leading to the formation of eggs with two 
copies of chromosome 21 which, if fertilized, would result in a zygote with full trisomy for 
chromosome 21 [11].  
      That paper was followed by over 50 case-control studies investigating the potential contribution 
of folate-pathway gene polymorphisms as maternal risk factors for the birth of a child with DS 
(reviewed in [13]). Systematic reviews and meta-analyses of those papers revealed that the MTHFR 
677C>T polymorphism is likely to be a maternal risk factor for a DS birth, particularly in women 
subjected to nutritional and/or environmental factors leading to reduced folate bioavailability [2,13-
16].  
       Accumulating evidence is revealing that the MTHFR gene is regulated by promoter 
methylation, and increased MTHFR promoter methylation has been observed in semen DNA of 
infertile men [17-19], in DNA extracted from cancerous tissues [20,21], in blood DNA of patients 
with cardiovascular pathology or renal disease [22,23], as well as in blood and placenta DNA of 
women with pre-eclampsia [24]. Those studies revealed that increased promoter methylation levels 
of this gene result in reduced MTHFR protein activity, thus increasing the risk of various human 
illnesses [17-24]. Several metabolic genes show inter-individual variability in promoter methylation 
levels, resulting in inter-individual changes in protein activity similar to those conferred by genetic 
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polymorphisms [25]. However, to the best of our knowledge, there is no available data on MTHFR 
promoter methylation levels in MDS tissues.  
      Therefore, in the present study, we investigated MTHFR promoter methylation levels searching 
for difference between DNA extracted from peripheral lymphocytes of MDS and matched control 
mothers. We also searched for correlation between MTHFR promoter methylation and 
micronucleus frequency, an established biomarker of genome instability. 
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2. Materials and Methods 
 
2.1. Study Population 
 
      Peripheral blood samples were available from 40 women who had a DS child with 
karyotipically confirmed trisomy 21 and 44 healthy women matched with the case mothers for age 
at sampling. Control mothers had at least one healthy child and no experience of miscarriages, 
abnormal pregnancies, or children affected by genetic disorders in their life. All women were aged 
less than 35 years when they conceived (mean age at conception 28.4 ± 4.9 years). Blood samples 
were collected by the medical personnel of either the Pisa University Hospital (Pisa, Italy) or the 
paediatric Hospital ‘‘IRCCS Stella Maris Foundation’’ (Pisa, Italy), and control mothers were 
recruited among people working at the above Hospitals, at the University of Pisa, or among healthy 
volunteers. Blood samples were not collected at the time of birth but often some years later when 
women brought their children to the recruiting Hospitals for medical checks. Therefore, we paid 
extreme caution to match case and control mothers for age at sampling (Table 1). Peripheral blood 
samples from all the women included in the present study were originally collected in the frame of a 
previous study aimed at evaluating chromosome damage events in peripheral lymphocytes [4]. 
Therefore, data on the frequency of binucleated micronucleated (BNMN) lymphocytes were 
collected at the time of blood drawing by means of the cytokinesis-block micronucleus assay 
according to the procedure previously described by us [3] and were already available from our 
cohort [4,26]. Table 1 presents the mean frequency of BNMN lymphocytes in MDS and control 
mothers. 
      The individuals included in the study have been selected after the administration of a validated 
questionnaire [3] designed to document their previous conditions in order to apply the adopted 
exclusion criteria. Particularly, all women included in the study were healthy at the time of blood 
collection and had no documented medical or occupational history of exposure to physical, 
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biological or chemical agents known or suspected to interfere with DNA methylation or with the 
micronucleus frequency in the three months preceding blood drawing. For instance, alcohol 
consumption, viral infection, or the current use of pharmacological products known or suspected to 
interfere with DNA methylation, such as for example folate or B vitamin supplements or epigenetic 
drugs, were used as exclusion criteria. Case and control mothers were matched for smoking habits 
(Table 1). 
    All mothers (MDS and controls) were white Caucasians and residents of central Italy at 
interview. Written informed consent for inclusion in the study was obtained from each subject. The 
Ethics Committee of the Scientific Institute IRCCS Stella Maris Foundation approved the study, 
and all the samples were processed blind, in accordance with the Declaration of Helsinki.  
     
2.2. Extraction of genomic DNA and bisulfite modification: 
 
      Peripheral blood samples were collected from each subject in EDTA tubes, and stored at -20°C 
until assayed. DNA samples were extracted from peripheral blood cells of each subject using the 
QIAmp DNA Blood Mini Kit (Qiagen, Milan, Italy, Catalogue N° 51106) following the 
manufacturer’s protocol. The extracted DNA was quantified using a Nano Drop ND 2000c 
spectrophotometer (NanoDrop Thermo Scientific). 200 ng of DNA from each sample were treated 
with sodium bisulfite in order to convert all unmethylated cytosines into uracil. The EpiTect 
Bisulfite Kit (Qiagen, Milan, Italy, Catalogue N° 59104) was used for this purpose, following the 
manufacturer’s instructions. All the analyses were performed simultaneously at the Medical 
Genetics laboratory of the University of Pisa.  
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2.3. Methylation analysis 
 
      Methylation sensitive-high resolution melting (MS-HRM) technique was applied to evaluate 
MTHFR methylation levels using a CFX96 Real-Time PCR detection system (Bio-Rad, Milan, 
Italy). Particularly, we studied a CpG island in the promoter/5’-untranslated (UTR) region of the 
MTHFR gene spanning from +30 to +184 from the transcription start site and containing 7 CpG 
sites whose methylation levels were found to be inversely correlated with gene expression levels in 
human lung cancer cells [20]. Table 2 shows the sequence of the primers, the annealing temperature 
(Ta), the length of the amplicon, the studied region, and the number of CpG sites within it. MS-
HRM analyses were performed using a protocol recently developed, validated with pyro-
sequencing, and fully described by us [27]. 
      Each sample was run in duplicate. Fully methylated and unmethylated DNA (EpiTect 
methylated and unmethylated human control DNA, bisulfite converted, Qiagen, Milan, Italy, 
Catalogue N° 59695) were mixed to obtain the following ratios of methylation: 0%, 12,5%, 25%, 
50%, 75%, 100%. Standard curves with known methylation ratios were included in each assay and 
used to deduce the methylation ratio of each sample (Figure 1). In order to obtain single 
methylation percentage values from MS-HRM assays, rather than a range, we applied an 
interpolation method recently developed and described by us [28], that allowed obtaining precise 
HRM methylation values.  
     All the employed procedures have been recently fully described and validated by us, and any 
further technical data on the set-up and validation procedures of the MS-HRM protocol for the 
analysis of MTHFR promoter methylation can be found in our recent methodological paper [27]. 
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2.4. Statistical analysis  
 
      Differences in mean methylation levels of the MTHFR gene between groups were compared by 
analysis of variance (ANOVA) correcting for age at sampling and smoking habits. ANOVA was 
also used to evaluate the contribution of smoking habits to the studied endpoints. Linear regression 
analysis was performed to search for correlation between age at sampling and MTHFR gene 
methylation levels, between age at sampling and the BNMN frequency, and between MTHFR gene 
methylation levels and the BNMN frequency. Analyses were performed with the STATGRAPHICS 
5.1 Plus software package for Windows. The statistical power of the study was evaluated with the 
online calculator ClinCalc.com (http://clincalc.com/Stats/SampleSize.aspx). A P value < 0.05 was 
considered as statistically significant. 
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3. Results 
  
      Figure 2 shows the mean MTHFR methylation levels obtained in MDS and control mothers. We 
observed a mean MTHFR promoter methylation of 33.3 ± 8.1% in MDS and of 28.3 ± 5.8% in 
control mothers (Crude p value = 0.002; Adjusted p value = 0.001). The sample size was chosen to 
have an a-priori power of more than 80% to detect an average 5% DNA methylation difference 
between groups, which represents the statistical power usually required for genome-wide DNA 
methylation studies [29]. A post-hoc analysis performed using the observed means and standard 
deviations revealed that the present study has 89.7% power to detect the observed methylation 
difference between groups.  
      Linear regression analysis revealed no correlation between MTHFR methylation and age at 
sampling (r = 0.02; p = 0.84). Data on chromosome damage events were already available from our 
cohort and, as shown in Table 1, the mean frequency of BNMN lymphocytes in MDS was 
significantly higher if compared to the control mothers (16.1 ± 8.6‰ vs 10.5 ± 4.3‰; p = 0.0004) 
(Table 1). Linear regression analysis revealed correlation between age at sampling and the 
frequency of BNMN lymphocytes (r = 0.25; p = 0.04), furthermore we observed a significant 
correlation between MTHFR promoter methylation and BNMN frequency (r = 0.33; p = 0.006) 
(Figure 3). 
      We already observed that smoking habits had no significant effect on the BNMN frequency in 
our cohort [4]. ANOVA analysis also revealed no significant contribution of smoking habits to 
MTHFR promoter methylation levels (smokers vs. never-smokers: p = 0.20; smokers + ex-smokers 
vs. never-smokers: p = 0.60). With a total of 64 never-smokers and 20 smokers and ex-smokers, we 
had 80% power to detect a mean methylation difference of 5% or higher between groups. 
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4. Discussion 
 
      In the present study we investigated MTHFR promoter methylation in blood DNA of women 
who conceived a child with DS in young age and matched control women, observing that MDS 
have a significantly higher methylation level of the gene under investigation than control mothers. 
In addition, a significant correlation between MTHFR promoter methylation levels and the 
frequency of BNMN lymphocytes was observed in our cohort.  
      MTHFR is one of the major enzymes of the folate metabolic pathway, whose genetic 
polymorphisms have been often associated with chromosome damage and maternal risk of birth of 
a child with DS [11,30]. DNA methylation in the promoter region of a gene is an epigenetic event 
resulting in reduced gene expression, and there is accumulating evidence of increased MTHFR 
promoter methylation in several human pathological conditions [17-24]. In the present study we 
investigated a functional CpG island in the promoter region of the MTHFR gene whose methylation 
levels have previously been linked to gene expression levels [20]. To the best of our knowledge the 
present is the first study addressing the methylation levels of a gene involved in folate metabolism 
in MDS, and present results suggest that MTHFR promoter methylation is increased in MDS and 
correlates with markers of genome instabily. Therefore, present results support a link between 
impaired folate metabolism and chromosome damage in those women. 
      One of the major limits for the study of the molecular mechanisms leading to chromosome 21 
malsegregation is the unavailability of human egg cells from MDS, so that most of the studies 
aimed at linking folate metabolism to chromosome 21 malsegregation have been performed with 
surrogate cells and tissues, including peripheral lymphocytes [3-7]. In this regard, in vitro studies in 
human lymphocytes have shown that folate restriction induces chromosome 21 aneuploidy [31,32]. 
Similarly, the studies performed so far in peripheral lymphocytes from MDS revealed that those 
cells are characterized by several markers of genome instability and premature ageing, including an 
increased frequency of micronuclei, short telomeres, and global changes in DNA methylation [3-
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10]. Those biomarkers could be indicators of altered pathways, such as impaired folate metabolism, 
accounting for an increased risk to give birth to a DS child in young age or to develop age-related 
neurodegenerative diseases later in life [3-10].                                                  
       In order to minimize the contribution of environmental factors and poly-medication to the 
observed MTHFR methylation levels we adopted very stringent inclusion criteria to exclude from 
the study alcohol consumers, users of vitamin supplements, or people with a documented 
occupational or medical exposure to chemical, physical or biological agents known or suspected to 
interfere with DNA methylation or micronucleus formation. In addition, to minimize the effects of 
ethnic or geographical factors, case and control mothers were all Caucasians and residents of central 
Italy (Pisa and neighbouring areas) at recruitment. Furthermore, we restricted our analysis to 
women who conceived before 35 years of age, because after that age limit the risk for DS is mainly 
due to advanced maternal age [1]. Unfortunately, in most of the cases we could not measure 
MTHFR methylation soon after pregnancy, but often some to several years later. However, there 
was no correlation between age at sampling and MTHFR promoter methylation in our cohort. Some 
of the women (20 out of 84) were smokers or ex-smokers, but their exclusion would have 
drastically reduced the statistical power of the study. Smoking is a known environmental factor able 
to induce changes in DNA methylation, its contribution to MTHFR promoter methylation is 
controversial [20,22], and no significant effect of smoking to global DNA methylation levels was 
observed in lymphocytes of MDS [10]. In the present study case and control mothers were matched 
for smoking habits and we found no significant effect of smoking to MTHFR promoter methylation 
levels. However, due to the relatively small sample-size of our cohort, additional studies are 
recommended to further address the contribution of smoking to gene promoter methylation in blood 
DNA of MDS. 
      Limitations of the present study are the relatively small case-control cohort and the iclusion of 
only Caucasian women residents of central Italy. Therefore, the present must be considered as a 
pilot study to evaluate MTHFR gene methylation in MDS, and confirmation is required in 
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subsequent cohorts as well as in other populations than Italians. Indeed, many authors have 
demonstrated that geographic and ethnic factors can modulate folate metabolism as well as DNA 
methylation reactions [13-16]. The present is also a retrospective study based on the analysis of 
DNA samples obtained from women who conceived a DS child when they were young. Prospective 
studies are therefore required in order to address whether or not increased MTHFR promoter 
methylation at peri-conception is linked to an increased maternal risk for a DS birth.  
      Overall, the present study pointed out an increased MTHFR promoter methylation in 
lymphocytes from MDS and a correlation between MTHFR promoter methylation levels and 
chromosome instability in those cells. Very interestingly, recent studies have shown that MTHFR 
promoter methylation is also linked to circulating folate, vitamin B12 and Hcy levels in individuals 
affected by Alzheimer’s disease, cardiovascular disease, as well as in healthy aged subjects, 
suggesting that the MTHFR methylation status could be a mediator of impairments of the folate 
metabolic pathway [22,27,33]. Therefore, we suggest that an increased MTHFR promoter 
methylation in lymphocytes of MDS could contribute to impaired folate metabolism in those cells 
with similar effects of those exerted by genetic polymorphisms, serving as a potential upstream 
player in genomic instability related disorders, such as chromosome 21 malsegregation or age-
related neurodegeneration [34-36]. 
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5. Conclusions 
 
      In summary, in the present pilot study investigating the methylation status of the MTHFR gene 
in peripheral lymphocytes, we observed that women who conceived a child with DS in young age 
have a statistically significant higher promoter methylation than matched control women. 
Furthermore, we observed that MTHFR promoter methylation correlates with chromosome damage 
evaluated as the frequency of BNMN lymphocytes. Many authors observed increased MTHFR 
promoter methylation in human diseases characterized by impaired folate metabolism, such as for 
example cancer, vascular disorders and male infertility, and there is accumulating evidence of 
correlation between MTHFR promoter methylation and impaired folate metabolism [17-26]. 
Functional MTHFR genetic polymorphisms linked to reduced protein activity represent the most 
frequently studied candidate polymorphisms in genetic association studies for the maternal risk of 
birth of a child with DS [13-16]. Changes in MTHFR promoter methylation are increasingly 
recognised as a source of inter-individual variability in protein activity whose effects might be 
similar to those conferred by genetic polymorphisms, but except for the present study no data is yet 
available concerning the MTHFR epigenetic regulation in MDS [13,25]. Therefore, present data are 
indicative that not only mutations in folate-pathway genes, but also their epimutations are likely to 
contribute to the increased genomic instability observed in cells from MDS, suggesting that they 
could play a role in the risk of birth of a child with DS, as well as in the onset of age related 
diseases in those women. 
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Table 1. Demographic characteristics of mothers of DS children (MDS) and control mothers. 
 
 
 
 
 
 
 
 
 
 
 
 
a Student’s T test. 
b Fisher exact test. 
c Analysis of variance (ANOVA) with corrections for age at sampling and smoking habits. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable 
 
MDS  
N° = 40 
 
Control mothers 
N° = 44 
 
p-Value 
 
 
Age at sampling: 
years (mean ± SD) 
 
46.1 ± 11.5 
 
47.8 ± 7.1 0.41a 
 
never-smokers 
 
ex-smokers 
 
smokers 
 
 
BNMN ‰  
(mean ± SD) 
 
31 (77.5%) 
 
4 (10.0%) 
 
5 (12.5%) 
 
 
16.1 ± 8.6 
 
 
33 (75.0%)      
 
3 (7.0%) 
 
8 (18.0%) 
 
 
10.5 ± 4.3 
 
0.69 b 
 
 
 
 
 
 
0.0004 c 
 
 
	   23	  
 
 
Table 2. Sequence of the primers, annealing temperature (Ta), length of the amplicon, studied 
region and number of CpG sites. 	  
Primer sequences Ta Amplicon 
length 
Promoter region 
CpG 
sites 
 
F: 5’-TTTTAATTTTTGTTTGGAGGGTAGT-3’ 
R: 5’- AAAAAAACCACTTATCACCAAATTC-3’ 
54°C 155 bp From +30 
to +184 
7 
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Figure Legends 
 
 
Figure 1. Melting curve of the MTHFR gene showing the standard samples with known 
methylation percentage (0%, 12.5%, 25%, 50%, 75%, 100%) and a sample in duplicate (indicated 
with an arrow). 
 
Figure 2. Mean methylation levels of the MTHFR promoter in mothers of Down syndrome 
individuals (MDS) and control women. We observed a mean MTHFR promoter methylation of 
33.3% in MDS and of 28.3% in control mothers (p = 0.001, ANOVA with corrections for age at 
sampling and smoking habits). The graph shows means ± standard errors of the means. 
 
Figure 3. Linear regression analysis between MTHFR promoter methylation and BNMN frequency:  
(r = 0.33; p = 0.006). 
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Figure 2 
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Figure 3 
